{"id":50876,"date":"2025-12-15T22:44:06","date_gmt":"2025-12-15T14:44:06","guid":{"rendered":"https:\/\/flcube.com\/?p=50876"},"modified":"2025-12-30T21:03:20","modified_gmt":"2025-12-30T13:03:20","slug":"hengrui-nmpa-approves-four-clinical-trials-advancing-oncology-and-metabolic-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50876","title":{"rendered":"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that China\u2019s National Medical Products Administration (NMPA) approved clinical trials for four pipeline assets: <strong>SHR\u2011A1811 (SC)<\/strong>, <strong>RSS0343<\/strong>, <strong>HRS9531<\/strong>, and <strong>HRS\u20111780<\/strong>, spanning oncology, respiratory, metabolic, and cardiovascular diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-approvals-overview\">Clinical Trial Approvals Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Formulation<\/th><th>Mechanism<\/th><th>Indication<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>SHR\u2011A1811 (SC)<\/strong><\/td><td>Subcutaneous injection<\/td><td>HER2 ADC<\/td><td>Advanced solid tumors<\/td><td>Clinical trial<\/td><\/tr><tr><td><strong>RSS0343<\/strong><\/td><td>Oral tablet<\/td><td>Novel anti\u2011inflammatory small molecule<\/td><td>Chronic rhinosinusitis without polyps, COPD<\/td><td>Clinical trial<\/td><\/tr><tr><td><strong>HRS9531<\/strong><\/td><td>Injection<\/td><td>GIPR\/GLP\u20111R dual agonist<\/td><td>MASH<\/td><td>Clinical trial<\/td><\/tr><tr><td><strong>HRS\u20111780<\/strong><\/td><td>Oral tablet<\/td><td>Mineralocorticoid receptor antagonist<\/td><td>Heart failure (LVEF \u226540%)<\/td><td>Clinical trial<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-individual-asset-profiles\">Individual Asset Profiles<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-shr-a1811-sc\">SHR\u2011A1811 (SC)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Background:<\/strong> IV formulation approved in China (May\u202f2025) for HER2\u2011mutant NSCLC<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First subcutaneous HER2 ADC for solid tumors; maintains efficacy with improved convenience<\/li>\n\n\n\n<li><strong>Market:<\/strong> Global HER2 ADC market $7\u202fbillion; SC route addresses outpatient treatment demand<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-rss0343\">RSS0343<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novelty:<\/strong> <strong>First\u2011in\u2011class<\/strong> oral anti\u2011inflammatory; no approved global\/China equivalents for chronic rhinosinusitis without polyps or COPD<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Potent, highly selective Class\u202f1 small molecule with strong preclinical efficacy<\/li>\n\n\n\n<li><strong>Market:<\/strong> COPD affects >100\u202fmillion in China; rhinosinusitis market \u00a55\u202fbillion<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hrs9531\">HRS9531<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> GIPR\/GLP\u20111R dual agonist; regulates glucose\/lipid metabolism, suppresses appetite<\/li>\n\n\n\n<li><strong>Indication:<\/strong> MASH (Metabolic Dysfunction\u2011Associated Steatohepatitis)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Expected to improve hepatic lipid accumulation, reduce inflammation\/fibrosis<\/li>\n\n\n\n<li><strong>Market:<\/strong> Global MASH market projected $35\u202fbillion by 2030; China MASH prevalence >30\u202fmillion<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hrs-1780\">HRS\u20111780<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Mineralocorticoid receptor antagonist for heart failure with LVEF \u226540%<\/li>\n\n\n\n<li><strong>Market:<\/strong> HFpEF affects ~50% of 6\u202fmillion heart failure patients in China; complements existing ARNI\/SGLT2i standards<\/li>\n\n\n\n<li><strong>Competition:<\/strong> Differentiated from finerenone (non\u2011steroidal MRA) with improved selectivity profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Hengrui:<\/strong> <strong>Four parallel pipeline advancements<\/strong> demonstrate R&amp;D breadth; RSS0343\u2019s <strong>first\u2011in\u2011class<\/strong> status and HRS9531\u2019s <strong>MASH<\/strong> entry position company in high\u2011growth markets; builds on SHR\u2011A1811\u2019s commercial success.<\/li>\n\n\n\n<li><strong>For Investors:<\/strong> Validates <strong>\u00a53\u20114\u202fbillion annual R&amp;D investment<\/strong> (2023\u20112025); multiple shots on goal reduce pipeline risk; potential for <strong>global out\u2011licensing<\/strong> of ADC and metabolic assets.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Strengthens China\u2019s <strong>innovation pipeline<\/strong> in respiratory and metabolic diseases; MASH and HFpEF programs address <strong>massive unmet needs<\/strong> with aging population.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial timelines, market size estimates, and competitive positioning. Actual results may differ due to regulatory feedback, clinical risks, or competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201376_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121201376_c.\"><\/object><a id=\"wp-block-file--media-a8a5710e-48c2-442f-ba6a-db16000082d4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201376_c.pdf\">2025121201376_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201376_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a8a5710e-48c2-442f-ba6a-db16000082d4\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201374_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121201374_c.\"><\/object><a id=\"wp-block-file--media-4284ebc7-835e-4cce-a52f-189f111f7876\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201374_c.pdf\">2025121201374_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201374_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4284ebc7-835e-4cce-a52f-189f111f7876\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201372_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121201372_c.\"><\/object><a id=\"wp-block-file--media-be32f8d0-ee38-4de3-b8bf-3c7f7e090552\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201372_c.pdf\">2025121201372_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201372_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-be32f8d0-ee38-4de3-b8bf-3c7f7e090552\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201350_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121201350_c.\"><\/object><a id=\"wp-block-file--media-8f3921ed-1c58-4cf7-81a1-87466b517fd8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201350_c.pdf\">2025121201350_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121201350_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8f3921ed-1c58-4cf7-81a1-87466b517fd8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China\u2019s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50882,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,69,2586,4228,76,852],"class_list":["post-50876","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-cvd","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-nash","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China\u2019s National Medical Products Administration (NMPA) approved clinical trials for four pipeline assets: SHR\u2011A1811 (SC), RSS0343, HRS9531, and HRS\u20111780, spanning oncology, respiratory, metabolic, and cardiovascular diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50876\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China\u2019s National Medical Products Administration (NMPA) approved clinical trials for four pipeline assets: SHR\u2011A1811 (SC), RSS0343, HRS9531, and HRS\u20111780, spanning oncology, respiratory, metabolic, and cardiovascular diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50876\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T14:44:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T13:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1515.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline\",\"datePublished\":\"2025-12-15T14:44:06+00:00\",\"dateModified\":\"2025-12-30T13:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1515.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"CVD\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"NASH\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50876#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50876\",\"name\":\"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1515.webp\",\"datePublished\":\"2025-12-15T14:44:06+00:00\",\"dateModified\":\"2025-12-30T13:03:20+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China\u2019s National Medical Products Administration (NMPA) approved clinical trials for four pipeline assets: SHR\u2011A1811 (SC), RSS0343, HRS9531, and HRS\u20111780, spanning oncology, respiratory, metabolic, and cardiovascular diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50876\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1515.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1515.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50876#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China\u2019s National Medical Products Administration (NMPA) approved clinical trials for four pipeline assets: SHR\u2011A1811 (SC), RSS0343, HRS9531, and HRS\u20111780, spanning oncology, respiratory, metabolic, and cardiovascular diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50876","og_locale":"en_US","og_type":"article","og_title":"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline","og_description":"Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China\u2019s National Medical Products Administration (NMPA) approved clinical trials for four pipeline assets: SHR\u2011A1811 (SC), RSS0343, HRS9531, and HRS\u20111780, spanning oncology, respiratory, metabolic, and cardiovascular diseases.","og_url":"https:\/\/flcube.com\/?p=50876","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-15T14:44:06+00:00","article_modified_time":"2025-12-30T13:03:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1515.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50876#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50876"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline","datePublished":"2025-12-15T14:44:06+00:00","dateModified":"2025-12-30T13:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50876"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50876#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1515.webp","keywords":["Cancer","Clinical trial approval \/ initiation","CVD","Hengrui Pharmaceuticals","HKG: 1276","NASH","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50876#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50876","url":"https:\/\/flcube.com\/?p=50876","name":"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50876#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50876#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1515.webp","datePublished":"2025-12-15T14:44:06+00:00","dateModified":"2025-12-30T13:03:20+00:00","description":"Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China\u2019s National Medical Products Administration (NMPA) approved clinical trials for four pipeline assets: SHR\u2011A1811 (SC), RSS0343, HRS9531, and HRS\u20111780, spanning oncology, respiratory, metabolic, and cardiovascular diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50876#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50876"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50876#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1515.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1515.webp","width":1080,"height":608,"caption":"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50876#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1515.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50876"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50876\/revisions"}],"predecessor-version":[{"id":50883,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50876\/revisions\/50883"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50882"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}